nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-C02874FC·Framework v5.9·Pipeline v0.4·Evaluated 08 Oct 2026·OECD: 3.1 Basic medicine·Subfield: Physiology·Basis: Full text·Type: Laboratory experiment

Longitudinal multiphoton imaging of cerebral amyloid angiopathy in response to anti-ApoE4 immunotherapy in mice.

Bonnar et al.Bonnar, Saadi, Sanchez-Mico et al.·2026·Molecular neurodegeneration·10.1186/s13024-026-00957-x ↗

Primary claim

there was a modest shrinkage of the smallest parenchymal fibrillar plaques but that fibrillar CAA on pial arterioles was not actively removed

Tentative · CAA was tracked longitudinally, but plaque shrinkage followed post hoc size stratification after a null total-area result
In brief

Longitudinal imaging narrows HAE-4’s therapeutic mechanism, but cranial-window constraints and unsupported comparative-safety framing limit its translational force.

ReliabilityNo concerns4 of 4 checks completeSee what was checked ↓
Fragile — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.
Abstract

BACKGROUND: There are no available treatments to halt or slow the progression of cerebral amyloid angiopathy (CAA), a disease neuropathologically characterized by the deposition of amyloid-β (Aβ) within the walls of the cerebrovasculature. Recently a novel therapeutic strategy has been described, targeting non-lipidated ApoE4 that co-deposits with Aβ, resulting in lower levels of Aβ across the brain. To understand the therapeutic potential for patients with CAA, we sought to determine if this global reduction in Aβ deposits corresponds to the active removal of existing aggregates in the vasculature and if so, whether this may improve vascular function over time.

METHODS: Cranial windows were implanted in 9-10-month-old 5xFAD mice expressing human APOE4 to facilitate chronic, unanesthetized imaging using in vivo multiphoton microscopy. Mice were treated weekly with anti-ApoE4 immunotherapy (HAE-4) or control IgG (50 mg/kg). Parenchymal and vascular Aβ burden as well as vascular function were measured in vivo before and during treatment. Post-mortem brains were assessed for CAA, parenchymal Aβ plaques and iron deposits. In a separate study, 5xFAD mice were treated with weekly HAE-4 or control IgG with the same doses of antibodies from 8 to 10 months of age in the absence of cranial windows.

RESULTS: Treatment with HAE-4 resulted in reduction of total Aβ plaque area post-mortem in mice and shrinkage of existing smaller plaques imaged with in vivo multiphoton microscopy. Vascular fibrillar Aβ under the cranial window conversely increased over time either with or without HAE-4 treatment and there was no treatment-associated improvement in vascular function in cortical arterioles in the areas measured in vivo. There was no evidence of hemorrhagic events linked to treatment, however there was significant immune cell activation. In 5xFAD mice treated without a cranial window, there was a reduction in plaques and CAA as previously described in HAE-4 vs. control treated mice.

CONCLUSIONS: Anti-ApoE4 immunotherapy, as shown previously, decreased the overall amount of Aβ. It also appeared to remove some existing plaque Aβ without measurable effects on vascular fibrillar Aβ deposits or vascular function in areas measured in vivo under a cranial window. The absence of treatment-associated hemorrhagic events may offer a comparative advantage relative to anti-Aβ immunotherapy.

Key Claims

Primary finding · Tentative

there was a modest shrinkage of the smallest parenchymal fibrillar plaques but that fibrillar CAA on pial arterioles was not actively removed

Fragile — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.

CAA was tracked longitudinally, but plaque shrinkage followed post hoc size stratification after a null total-area result

Results, first subsection
Quote verified
Secondary · Supported

there was no treatment-associated improvement in vascular function in cortical arterioles in the areas measured in vivo

multiple longitudinal vessel measures were unchanged, although samples were modest and no baseline deficit was present

Abstract; Results, Figs. 2–4
Quote verified
Secondary · Supported

In 5xFAD mice treated without a cranial window, there was a reduction in plaques and CAA as previously described in HAE-4 vs. control treated mice

the larger nonsurgical cohort showed consistent terminal reductions, though detailed methods were deferred to supplementary material

Abstract; Results, Fig. 6
Quote verified

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#contribution

Longitudinal tracking answers the mechanism question

Repeated multiphoton imaging followed the same CAA-bearing vessels and plaques before and during treatment, directly testing whether existing deposits were removed rather than inferring clearance from terminal burden.

↳ Methods, Treatment Paradigm and Vascular and CAA Imaging; Fig. 1

#methodological rigour

Blinded animal-level experimental execution

The experimenter was blinded during dose preparation, injections, data collection, and analysis; fields were selected before treatment; and figure legends identify the animal average as the statistical unit.

↳ Methods, Treatment Paradigm; Figs. 1–6

#positioning

Discordant findings receive integrated analysis

The Discussion distinguishes superficial longitudinal imaging from hemisphere-level histology and examines assay, surgery, timing, pathology stage, and sampling as explanations for disagreement with prior work.

↳ Discussion, sections addressing prior vascular-function findings and post-mortem discordance

Limitations

#methodological rigour

Small-plaque result is post hoc

Total parenchymal plaque area was not significantly changed before plaques were divided into four size groups, after which only the smallest group showed a treatment effect. No multiplicity correction across these exploratory comparisons is described.

↳ Results, first subsection; Fig. 1D–F

#contribution

Window and cohort differences confound interpretation

CAA was not reduced in the small terminal windowed cohort but was reduced in a larger, younger nonsurgical cohort treated for a different duration. These differences prevent a clean attribution of the discordance to the cranial window.

↳ Results, Figs. 5D and 6D/G; Discussion

#reporting

Comparative safety claim exceeds design

The absence of a treatment-associated hemorrhage signal in mice does not establish HAE-4 as safer than anti-Aβ immunotherapy because the current study lacks a concurrent anti-Aβ comparator and reports immune activation.

↳ Abstract; Results, Figs. 5–6; Conclusions

Does this match your read? Add your assessment ↓

Nabu Commentary

The study’s strongest feature is its longitudinal tracking of the same CAA-bearing vessels, which directly addresses whether lower terminal burden reflects removal of established deposits. The main in vivo result is a well-scoped negative finding, while the positive smallest-plaque result carries less weight because it followed a null total-area analysis and post hoc size stratification. Blinding, animal-level aggregation, repeated measures, and the larger nonsurgical cohort support methodological competence, but the windowed and nonsurgical cohorts differ in age, duration, and preparation. The Discussion handles these discrepancies carefully, whereas the claim of comparative safety extends beyond a design without a concurrent anti-Aβ arm.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
3.7±0.2

Contribution
3.6

The study meaningfully extends prior terminal work by following existing CAA-bearing vessels and plaques longitudinally, showing no active clearance in the imaged vessels. Its advance is moderated by a largely negative in vivo result, a post hoc plaque-size finding, and partial replication in the separate cohort.

Introduction; Results, first subsection; Figs. 1 and 6

“fibrillar CAA on pial arterioles was not actively removed”

Methodological Rigour
3.6

The design uses blinded treatment and analysis, preselected fields, repeated imaging of the same vessels, animal-level aggregation, and a separate nonsurgical cohort. Modest samples, window-related attrition, post hoc plaque binning, and incomplete power and randomization reporting limit execution.

Methods, Treatment Paradigm and Statistics; Figs. 1–6
Reporting
3.4

The paper clearly distinguishes absent in vivo CAA removal from lower terminal Aβ burden and openly describes discordant findings. The claim that HAE-4 could be a safe alternative to anti-Aβ immunotherapy materially exceeds a study without a direct comparator.

Abstract; Discussion; Conclusions

“HAE-4 immunotherapy could be a safe alternative to anti-Aβ immunotherapy”

Positioning
4.0

The Discussion substantively reconciles the vascular-function findings with prior HAE-4 work and traces imaging, surgical, disease-stage, and sampling limitations to interpretation. The broader therapeutic context is less comprehensive, and parts of the mechanistic account remain speculative.

Discussion, paragraphs addressing prior vascular-function findings and in vivo/post-mortem discordance

Reliability

No concerns4 of 4 checks


Results checkClean

The reported numbers and statistics are consistent with the stated results.

Reporting and transparencyClean

No grounded reporting or conduct finding remains; antibody manufacture alone does not establish an undisclosed conflict of interest.

Conflict of interest: not stated · Ethics approval: declared · Data availability: not stated · Code availability: not stated

Reference IntegrityClean

33 references in manuscript 32 of 32 checkable references found in an index 1 are books, websites or datasets — counted, but not index-checkable

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Cardiovascular · Other cardiovascular and circulatory diseases
Type of advanceEmpirical
Route to useSuggested
AdvanceExtends
BeneficiariesCatch-all cause
CitationsToo early
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessControlled
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The primary claim about plaque shrinkage and lack of CAA removal was demonstrated only in controlled mouse model experiments with no human or clinical validation.

From the paper
“HAE-4 immunotherapy could be a safe alternative to anti-Aβ immunotherapy”

The paper names a possible therapeutic use of its findings for CAA patients but does not specify who would develop or deliver it.

Pathway

Drug developers and clinicians could pursue HAE-4 immunotherapy as a safer treatment to slow Aβ accumulation in CAA and Alzheimer's patients.

Barrier

The findings are limited to mouse models, show no removal of existing vascular amyloid, and require human trials confirming safety and efficacy before clinical use.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Comparing amyloid immunotherapy with cholinesterase inhibitors for Alzheimer's disease

    2026 · Neurology and psychiatry

    Evidence Score
    3.4±0.2
    Reliability
    No concerns
  2. Divergent toxicity mechanisms of amyloid-beta aggregates arising from a single aggregation reaction

    2026 · Basic medicine

    Primary claim

    aggregates enriched during the growth phase downregulated homeostatic microglial markers and induced TLR4-mediated microglial activation, cytokine production, and complement activation, leading to synaptic engulfment and severe disruption of neuronal activity

    Tentative
    Evidence Score
    2.8±0.2
    Reliability
    Caveats
  3. A timeline of tau-mediated synaptotoxicity

    2026 · Basic medicine

    Primary claim

    even brief tau oligomer exposure induces lasting bipartite synapse dysfunction and presenting a timeline of progressive pre- and post-synaptic degeneration.

    Tentative
    Evidence Score
    3.2±0.2
    Reliability
    No concerns

How the rubric works →